| Type of Cancer |
Biomarkers |
Approach and Limit of Detection |
References |
| Prostate |
PSA |
Immunosensor, imaging and localized SPR approaches, limit of detection ranges from 0.3 fM to 10 nM. |
[209-214] |
| Breast |
BRCA1
CA-15.3
LOX-12
CD24 |
DNA functionalized SPR sensor surface using vertical and lateral spacers, detection limit below 50 nM.
Au/ZnO activated films used for SPR sensor surface, detection limit of 0.025U/ml.
Antibody functionalized SPR sensor surface, detection limit is 9x10-2 ng/ml.
E-Selectin functionalized SPR sensor surface. |
[215]
[216]
[217]
[218] |
| Colorectal |
CEA
VEGF
Transgelin-2 & ALCAM/CD |
Immunosensor SPR using protein A or G or HRP conjugated antibody for signal enhancement, range of detection 25 ng/ml to 125 ng/ml
RNA aptamer funtionalized SPR sensor surface, limit of detection at pM
Polarized SPR imaging for signal sensitivity, detection limit 3 -6 ng/ml |
[219, 220]
[221]
[222] |
| Oral |
COX2 & IL-8 |
Immunosensor and microfluidic channel SPR, limit of detection 250 pM |
[223, 224] |
| Pancreatic |
AlCAM & hCG |
Immunosensor SPR or SPR imaging using antibody chip using an oligonucleotide linker, limits of detection are 0.5-1 ng/ml or 50 ng. |
[225, 226]
|
| Gastric |
MG-7 |
SPR biosensor |
[227] |
| Hepatic |
AFP |
ELISA type on SPR sensor, limit of detection 700 ng/ml |
[228] |
| Lung |
proGRP |
aptamer funtionalized SPR sensor surface |
[229] |
| Ovarian |
HE4 |
Localized SPR immunobiosensor for detecting HE4 in blood samples, limit of detection 4 pM. |
[230] |
